ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE(IABS-EU)

Their core work

IABS-EU is the European branch of the International Alliance for Biological Standardization, a non-profit dedicated to advancing the science of biological standardization — particularly for vaccines and biologics. They bring together regulators, manufacturers, and academics to develop consensus on quality standards, testing methods, and regulatory science for biological products. In H2020 projects, they contribute expertise on vaccine quality control, manufacturing consistency, and public-private governance frameworks for public health initiatives.

What they specialise in

How they've shifted over time

Their early H2020 work (2016-2018) centered on traditional biological standardization: vaccine lot consistency testing (VAC2VAC) and public health governance for influenza vaccine effectiveness (DRIVE). From 2020 onward, they pivoted toward more forward-looking topics — emergency response biologics with MANCO during COVID-19, and then advanced modelling approaches including AI and controlled human infection models in Inno4Vac. The shift suggests a move from retrospective quality assurance toward predictive and technology-driven approaches to vaccine development.

IABS-EU is evolving from a traditional standards body into a partner for next-generation vaccine development, increasingly engaging with AI modelling and human challenge trials.

How they like to work

IABS-EU always participates as a partner, never as coordinator — consistent with their role as a standards and governance body that convenes expertise rather than leading technical research. With 75 unique partners across 14 countries from just 4 projects, they operate in large, multi-partner consortia (averaging ~19 partners per project). This makes them an accessible, well-connected partner who brings regulatory and standardization credibility to any consortium without competing for the scientific lead.

Despite only 4 projects, IABS-EU has built a remarkably broad network of 75 unique partners across 14 countries, reflecting their role as a convener in large vaccine-focused consortia. Their network spans major European pharmaceutical and public health research hubs.

What sets them apart

IABS-EU occupies a rare niche as a non-profit international standardization body specifically focused on biological products in Europe. Unlike university labs or pharma companies, they serve as a neutral bridge between regulators, manufacturers, and researchers — making them uniquely valuable for projects that need regulatory science credibility. For consortium builders, adding IABS-EU signals commitment to quality standards and regulatory alignment, which strengthens proposals targeting vaccine and biologics topics.

Highlights from their portfolio

• VAC2VAC
  Their largest funded project (EUR 493K) tackling a fundamental challenge in vaccine manufacturing — proving batch-to-batch consistency without animal testing.
• Inno4Vac
  Their most recent and longest-running project (2021-2027), marking a strategic shift toward AI-driven and advanced in vitro models for vaccine development.
• MANCO
  A rapid-response COVID-19 project on monoclonal antibodies, demonstrating their ability to mobilize for pandemic emergencies despite being a standards-focused organization.